このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

2022年1月5日 更新者:Christopher Sweeney, MBBS、Dana-Farber Cancer Institute

A Phase 1 Study of Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer Before or After Progression on Docetaxel.

This research study is comparing the combination of drugs Crizotinib and Enzalutamide as a possible treatment for metastatic castration-resistant prostate cancer (mCRPC).

調査の概要

詳細な説明

  • A traditional 3+3 dose escalation scheme will be used to identify the recommended phase 2 dose (RP2D) of crizotinib when used in combination with standard fixed dose enzalutamide.
  • Patients who fulfill eligibility criteria will be entered into the trial to receive crizotinib and enzalutamide.
  • After the screening procedures confirm participation in the research study:

    • The participant will be given a study drug-dosing calendar for each treatment cycle. The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.

研究の種類

介入

入学 (実際)

24

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Massachusetts
      • Boston、Massachusetts、アメリカ、02115
        • Dana Farber Cancer Institute

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

説明

Inclusion Criteria:

  • Laboratory and diagnostic tests, such as MRIs and CT scans, required for eligibility must be documented from tests performed within 30 days prior to the date of registration.
  • The patient has pathologically confirmed adenocarcinoma of the prostate
  • The subject must have CRPC with castrate levels of serum testosterone less than 50 ng/dL.

    -- NOTE: Subjects must maintain a castrate state. If they have not had an orchiectomy must continue to receive LHRH or GnRH agonists unless intolerant.

  • Evidence of metastatic disease by radiographic imaging (bone scan or other nodal or visceral lesions on CT or MRI)
  • Prostate cancer progression since last prior therapy documented by PSA according to PCWG2 or radiographic progression according to modified RECIST criteria Version 1.1
  • No limit on number or type of prior therapies

    • Prior treatment with docetaxel is permitted but not required
    • Prior treatment with ketoconazole, estrogens, abiraterone or novel antiandrogens allowed, including past enzalutamide
    • Require at least a 6 week withdrawal period from the last dose of bicalutamide, or nilutamide or 4 weeks from last flutamide or enzalutamide dose Must have a documented PSA rise after stopping the antiandrogen --- Will require a 2 week washout period from last dose of ketoconazole, chemotherapy, or radiation
  • Prior radiation is allowed
  • Age ≥18 years
  • ECOG performance status <2 (See Appendix 1)
  • Life expectancy of greater than 6 months
  • Participants must have normal organ and marrow function as defined below:

    • Absolute neutrophil count ≥1,500/mcL
    • Hemoglobin ≥8 g/dL

      ---*Transfusions and erythropoietin supplementation permitted

    • Platelets ≥100,000/mcL
    • Total bilirubin within normal institutional limits (unless known Gilbert's syndrome)
    • AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal or ≤5X if presence of liver metastases

      --- *For patients with documented bone metastases, AST can be > 2.5x ULN if the investigator can provide evidence of no underlying liver dysfunction and thus, it is likely that the AST is originating from bone source.

    • Creatinine clearance ≥30 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
  • Able to swallow the study drug as a whole tablet
  • The effects of crizotinib and enzalutamide on the developing human fetus are unknown. For this reason and because investigational agents as well as other standard antiandrogen agents used in this trial may be teratogenic, men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of crizotinib administration.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Pathology consistent with small cell carcinoma of the prostate
  • Prior treatment with c-Met inhibitors
  • Participants who have received any other investigational systemic agents in the last 2 weeks.
  • Persistent grade >1 (NCI CTCAE v4.0) AEs due to investigational drugs that were administered more than 14 days before study enrollment with the exception of alocepia.
  • Participants with known brain metastases will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction or seizures that would confound the evaluation of neurologic and other adverse events.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to crizotinib or enzalutamide.
  • History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke or significant brain trauma, history of loss of consciousness or transient ischemic attack within 12 months of study entry).
  • Concomitant medications that would lower seizure threshold
  • Concomitant use of medications that may alter pharmacokinetics of crizotinib or enzalutamide. See section 5.5, but would exclude the use of strong CYP3A or CYP2C8 inhibitors, strong or moderate CYP3A inducers, CYP2C8, CYP3A4, CYP2C9 and CYP2C19 substrates with narrow therapeutic indice.

    -- Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list such as: http://medicine.iupui.edu/clinpharm/ddis/table.aspx

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

    • Clinically significant heart disease defined as:

      • Myocardial infarction within 6 months of Screening visit.
      • Uncontrolled angina within 3 months of Screening visit.
      • Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or subjects with history of congestive heart failure NYHA class 3 or 4 in the past, or history of anthracycline or anthracenedione (mitoxantrone) treatment, unless a screening echocardiogram or multi-gated acquisition scan (MUGA) performed within three months of the Screening visit results in a left ventricular ejection fraction that is ≥45%.
      • History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsade de pointes).
      • Prolonged corrected QT interval by the Fridericia correction formula (QTcF) on the screening electrocardiogram (ECG) > 470 msec.
      • History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place.
      • Hypotension (systolic blood pressure <86 mmHg) or bradycardia with a heart rate of <50 beats per minute on the Screening ECG, unless pharmaceutically induced and thus reversible (i.e. beta blockers) or known, chronic asymptomatic baseline heart rate.
      • Uncontrolled hypertension as indicated by a resting systolic blood pressure >170 mmHg or diastolic blood pressure >105 mmHg at the Screening visit.
      • No medications known to prolong the QT interval as crizotinib may increase the risk for QT prolongation
    • Thrombosis or vascular ischemic events within the last six months, such as deep venous thrombosis, pulmonary embolism, transient ischemic attack, cerebral infarction, or myocardial infarction
  • No medications known to prolong the QT interval as crizotinib may increase the risk for QT prolongation
  • Pregnant women are excluded from this study because women do not get prostate cancer, as they have no prostate.
  • No defined washout period from major or minor surgery is required but incisions must be fully healed.
  • HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with crizotinib or enzalutamide. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.
  • Inability to comply with study and/or follow-up procedures

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:crizotinib and enzalutamide

A traditional 3+3 dose escalation scheme will be used to identify the recommended phase 2 dose (RP2D) of crizotinib when used in combination with standard fixed dose enzalutamide.

  • Crizotinib- given orally daily-28 day cycle
  • Enzalutamide- given orally daily-28 day cycle
Crizotinib is an ATP-competitive small-molecule inhibitor of the ALK, c-Met/HGFR, RON, and ROS receptor tyrosine kinases.
他の名前:
  • PF-02341066
  • ザルコリ
Enzalutamide is an androgen receptor signaling inhibitor.
他の名前:
  • MDV3100
  • XTANDI

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Rate of dose limiting toxicity (DLT)
時間枠:28 Days
Rate of dose limiting toxicity (DLT) in the first 28 days of study therapy by dose level when escalating doses of crizotinib are combined with enzalutamide and when appropriate a GnRH agonist.
28 Days

二次結果の測定

結果測定
メジャーの説明
時間枠
Pharmacokinetics profiles of crizotinib and enzalutamide when used in combination
時間枠:C1D1, C2D1: baseline, 0.5, 1, 2, 4, 6, and 8 hours after dose; prior to dose on C1D2, C2D2, C1D15, C2D15 , C3D1
Pharmacokinetic parameters will be determined using noncompartmental methods with WinNonLin version 5.2. Maximum blood concentration (Cmax) and time of maximum blood concentration (tmax) will be determined by visual inspection. The area under the blood concentration-time curve (linear trapezoidal rule) will be determined between 0-24 hours (AUC0-24)/. The mean (+/- STDEM) concentration-time profiles of both crizotinib and enzalutamide will be presented for each dose.
C1D1, C2D1: baseline, 0.5, 1, 2, 4, 6, and 8 hours after dose; prior to dose on C1D2, C2D2, C1D15, C2D15 , C3D1
The number of patients who experience adverse events and laboratory abnormalities
時間枠:2 Years
The tolerability of the combination as defined as toxicity that results in study drug discontinuation or dose reduction that would not have been mandated by the protocol such as a DLT
2 Years

その他の成果指標

結果測定
メジャーの説明
時間枠
Time to radiologic disease progression
時間枠:2 years
Time to radiographic progression based on the Kaplan-Meier Method from study entry to documented disease progression.
2 years
Blood markers of bone turnover and changes in bone microenvironment
時間枠:2 years
Change in serum and bone-specific alkaline phosphatase and change in serum C-terminal telopeptides (CTx)
2 years
Change in quantity and gene expression of CTCs
時間枠:2 years
Assessment of DNA alterations through whole exome sequencing and RNA analysis to assess the ability to detect the AR-V7 transcriptional variant and individual markers of AR and MET signaling using PCR-based methods
2 years
Time to disease progression including PSA
時間枠:2 years
Time to radiographic progression based on the Kaplan-Meier Method from study entry to documented disease progression but with PSA values at corresponding timepoints.
2 years
Progression-free survival
時間枠:2 years
Time to progression free survival based on the Kaplan-Meier Method from study entry to documented disease progression.
2 years
Time to treatment failure
時間枠:2 yrs
Time to treatment failure from adverse event or progression
2 yrs
PSA response in patients who remain on therapy at 12 weeks
時間枠:2 yrs
PSA response; change in alkaline phosphatase, CTx, and CTCs will be summarized descriptively
2 yrs

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Christopher Sweeney, MD、Dana-Farber Cancer Institute

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2014年8月1日

一次修了 (実際)

2018年2月2日

研究の完了 (実際)

2022年1月3日

試験登録日

最初に提出

2014年7月30日

QC基準を満たした最初の提出物

2014年7月31日

最初の投稿 (見積もり)

2014年8月4日

学習記録の更新

投稿された最後の更新 (実際)

2022年1月6日

QC基準を満たした最後の更新が送信されました

2022年1月5日

最終確認日

2022年1月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

3
購読する